作者: Julie N. Leal , T. Peter Kingham
DOI: 10.1016/J.SOC.2014.09.005
关键词: Clinical trial 、 Primary liver cancer 、 Malignancy 、 Medicine 、 Artery infusion 、 Colorectal cancer 、 Chemotherapy 、 Oncology 、 Catheter 、 Internal medicine
摘要: To date, hepatic artery infusion (HAI) chemotherapy has primarily been investigated in the setting of colorectal cancer liver metastases (CRLM). Few studies have conducted North America regarding HAI for primary cancers (PLC) or noncolorectal (non-CRLM). Despite decades evaluation, controversy surrounding use still exists. In this article methods delivery, technical aspects catheter and pump insertion, specific complications are discussed. Outcomes clinical trials reviews CRLM, PLC, non-CRLM evaluated.